DNER and glioblastoma: INCB057643 is a novel BET inhibitor that is orally available and was already tested in phase-I clinical trials in patients with myelofibrosis and advanced malignancies [238], including GBM (Table 1; https://clinicaltrials.gov/ct2/results?cond=Glioblastoma&term=myc&cntry=&state=&city=&dist=&Search=Search; accessed on 12 January 2023).